Liporetro-D-peptides - a novel class of highly selective thrombin inhibitors. 2012

Alexey A Poyarkov, and Svetlana A Poyarkova, and Irina V Smirnova, and Valery P Kukhar
Institute of Bioorganic Chemistry and Petrochemistry of the Ukrainian National Academy of Sciences, 1, Murmanska St, Kyiv 94, 02660 Ukraine.

BACKGROUND Plasma serine protease thrombin plays a key role in coagulation, haemostasis and thromboembolic diseases. Direct thrombin inhibitors could be beneficial for future anticoagulant therapy. We have synthesized and studied liporetro-D-peptides - efficient thrombin inhibitors resistant to enzymatic degradation. METHODS Compounds X-D-Arg-D-Phe-OMe, where X=residue of lauric or myristic acid or 9-fluorenylmethoxycarbonyl, have been synthesized by conventional peptide synthesis in solution and their comparative inhibitory analysis in relation to thrombin, factor X, plasmin and trypsin has been conducted. RESULTS Modification of the synthetic liporetro-D-peptides with the myristic acid residue was the most successful one. This modification has dramatically increased the inhibition efficacy (Ki=0,17 μM) and selectivity toward the chosen target enzyme, thrombin, in comparison to factor X, plasmin and trypsin (more than 600, 900, and 5000-fold, respectively). CONCLUSIONS Our findings establish an important role of the fatty moiety in the structure of peptide inhibitors with regards to their potency and selectivity toward thrombin.

UI MeSH Term Description Entries
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D000991 Antithrombins Endogenous factors and drugs that directly inhibit the action of THROMBIN, usually by blocking its enzymatic activity. They are distinguished from INDIRECT THROMBIN INHIBITORS, such as HEPARIN, which act by enhancing the inhibitory effects of antithrombins. Antithrombin,Direct Antithrombin,Direct Antithrombins,Direct Thrombin Inhibitor,Direct Thrombin Inhibitors,Antithrombin, Direct,Antithrombins, Direct,Inhibitor, Direct Thrombin,Thrombin Inhibitor, Direct,Thrombin Inhibitors, Direct
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013917 Thrombin An enzyme formed from PROTHROMBIN that converts FIBRINOGEN to FIBRIN. Thrombase,Thrombin JMI,Thrombin-JMI,Thrombinar,Thrombostat,alpha-Thrombin,beta,gamma-Thrombin,beta-Thrombin,gamma-Thrombin,JMI, Thrombin

Related Publications

Alexey A Poyarkov, and Svetlana A Poyarkova, and Irina V Smirnova, and Valery P Kukhar
April 2002, Bioorganic & medicinal chemistry letters,
Alexey A Poyarkov, and Svetlana A Poyarkova, and Irina V Smirnova, and Valery P Kukhar
February 1993, Journal of medicinal chemistry,
Alexey A Poyarkov, and Svetlana A Poyarkova, and Irina V Smirnova, and Valery P Kukhar
November 2010, Bioorganic & medicinal chemistry letters,
Alexey A Poyarkov, and Svetlana A Poyarkova, and Irina V Smirnova, and Valery P Kukhar
August 2001, Chemistry (Weinheim an der Bergstrasse, Germany),
Alexey A Poyarkov, and Svetlana A Poyarkova, and Irina V Smirnova, and Valery P Kukhar
June 1975, The Kobe journal of medical sciences,
Alexey A Poyarkov, and Svetlana A Poyarkova, and Irina V Smirnova, and Valery P Kukhar
April 1995, Journal of medicinal chemistry,
Alexey A Poyarkov, and Svetlana A Poyarkova, and Irina V Smirnova, and Valery P Kukhar
January 2017, European journal of medicinal chemistry,
Alexey A Poyarkov, and Svetlana A Poyarkova, and Irina V Smirnova, and Valery P Kukhar
November 1994, Journal of medicinal chemistry,
Alexey A Poyarkov, and Svetlana A Poyarkova, and Irina V Smirnova, and Valery P Kukhar
October 2002, Bioorganic & medicinal chemistry letters,
Alexey A Poyarkov, and Svetlana A Poyarkova, and Irina V Smirnova, and Valery P Kukhar
November 1997, Journal of medicinal chemistry,
Copied contents to your clipboard!